Developer docs
API playgroundTry for free, no card

Search company profiles

Profusa

Full company profile

uuid000029n

Namestring
Profusa
Legal namestring
Profusa, Inc.
Websiteurl
profusa.com
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Profusa is a medical device company developing injectable, biologically compatible hydrogel microsensors (sub-millimeter diameter) that integrate with surrounding tissue to enable continuous, real-time biochemical monitoring from inside the body for 9+ months from a single hypodermic needle injection. The core hydrogel architecture is paired with a reusable Bluetooth-enabled optoelectronic reader patch, a smartphone application (iOS/Android), a cloud backend, and an NVIDIA-backed machine-learning layer that compensates for individual tissue variation to maintain accuracy over months without recalibration. The platform is supported by 85 global patents and more than $100M of cumulative investment, including $30M+ in non-dilutive grants from DARPA and NIH.

Profusa commercializes this platform through three product lines. Lumee Oxygen is an injectable tissue oxygen sensor delivering intra-operative and 28-day post-operative real-time oxygen monitoring for Critical Limb Ischemia intervention — a use case validated by a 2015 Journal of Vascular Surgery publication — with EU CE Mark conformity assessment under GMED targeted for Q3–early Q4 2026 and an FDA pivotal study targeted Q1 2026. Lumee Glucose is a continuous glucose monitor delivering 270+ days of monitoring from a single injection, with clinical-trial MARD of 10–12% and a projected ~$900/yr cost at >80% gross margin, targeting the full diabetes spectrum from T1D through prediabetes. The Data Discovery Platform converts continuous biochemical streams into clinical insights, with planned EMR integration and a physician portal. Profusa has also announced a ~$30M LOI to acquire BioInsights' PanOmics multi-omics diagnostics platform to extend into molecular diagnostics, initially targeting pancreatic cancer.

Commercially, Profusa is essentially pre-revenue with a planned FY2026 launch in Europe and the U.S. The company generates revenue today via per-procedure sales of CLI sensors at €600–€800 per case, €10,000 starter kits (3 kits/center/year), a service-based CRO research-use-only offering, and (planned) ~$900/yr subscription pricing for the future Lumee Glucose CGM. Distribution in Europe is anchored by AngioPro GmbH (Germany, Benelux, Austria, UK, Scandinavia), MedSell (France), and Dismeval (Spain), collectively covering roughly 35% of the EU population and ~200,000 annual Critical Limb Threatening Ischemia cases. Anchor clinical centers of excellence — Austria Medical Center, Paris Vascular Center, and Belgium Vascular Center — are pre-engaged. The company became public on Nasdaq via a July 2025 business combination with NorthView Acquisition Corp (ticker PFSA) and has since assembled a $22M PIPE, a $100M Equity Line of Credit with Ascent Partners, and additional convertible note facilities; it is also pursuing a strategic review with Tungsten Advisors amid a going-concern flag, Nasdaq listing transfer to the Capital Market tier, and shareholder-approved reverse stock split and debt conversion.

Short descriptiontext

Profusa is a medical device company commercializing injectable hydrogel biosensors for continuous tissue oxygen monitoring in critical limb ischemia and a long-duration continuous glucose monitor, with a planned multi-omics diagnostics expansion.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
implantable biosensors, continuous tissue monitoring, tissue oxygen monitoring, continuous glucose monitoring, medical device manufacturing
Industry1 code
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Commercial Physical & Biological Research8731
Product category
Implantable Medical Biosensors
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model4 records
1Procedure Revenue (CLI Sensors)
TypeHardware Sales
Description

Per-procedure sale of 4 sensors + 4 injection pens per CLI case, priced at €600–€800 per procedure, recurring with case volume at vascular surgery centers.

profusa.com
2Starter Kit Sales
TypeHardware Sales
Description

One-time sale of starter kits (iPad + preloaded software + sensors + adhesives) priced at €10,000 per kit, with target of 3 kits per center per year covering 200–1,500 procedures depending on center volume.

profusa.com
3Contract Research Organization (CRO) Research Services
TypeProfessional Services
Description

Service-based revenue from Lumee tissue oxygen platform deployed as research-use-only (RUO) offering in the CRO market for pharmaceutical R&D, preclinical studies, toxicology, wound healing, and oncology research applications; commercially available and targeted at $47.9B (2025) global CRO market.

globenewswire.com
4Future Data Monetization & AI-Driven Insights
TypeData Monetisation
Description

Planned/optional stream where Profusa's growing clinical dataset of real-time biochemical measurements is monetized through partnerships, research collaborations, and the physician portal; positioned as a compounding data asset.

profusa.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Technology or R&D
Pricing details4 tiers
1CLI Procedure: €600–€800 per procedure (4 sensors + 4 pens)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€600–€800 per procedure; 4 sensors + 4 injection pens per CLI case; volume-driven recurring revenue at vascular surgery centers.

profusa.com
2Starter Kit: €10,000 per kit
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

€10,000 per kit includes iPad + preloaded software + sensors + adhesives; 3 kits per center per year.

profusa.com
3Lumee Glucose CGM: ~$900/year projected
ModelSubscriptionBilling cadenceAnnual
Notes

Internal cost projection at >80% gross margin; 270+ day sensor life from a single injection; targets T1D through prediabetes at significantly lower cost than incumbent CGMs priced up to $7,000/yr.

profusa.com
4CRO Research-Use-Only Service (custom)
ModelOtherBilling cadencePay-as-you-go
Notes

Service-based revenue from continuous tissue oxygenation data delivered to pharmaceutical R&D and CRO customers; per-project engagement pricing not publicly disclosed.

globenewswire.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Lumee
Description

Product line of injectable hydrogel biosensor platforms for continuous tissue oxygen (Lumee Oxygen) and glucose (Lumee Glucose) monitoring, with companion Lumee Patch optical reader and Lumee App for iOS/Android.

profusa.com
+1 more record
Core offering1 text field

Profusa develops and manufactures an injectable, biologically compatible hydrogel microsensor platform that integrates with surrounding tissue to provide continuous, real-time biochemical monitoring for 9+ months from a single injection. Its commercial products include the Lumee Oxygen Platform (intra-operative and 28-day post-operative tissue oxygen monitoring for Critical Limb Ischemia), the Lumee Glucose Platform (a 270+ day continuous glucose monitor), and the AI-driven Data Discovery Platform (an NVIDIA-backed cloud analytics layer with planned EMR and physician portal integration).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 270+ day sensor functional life vs 7–14 days for conventional CGM devices (Senseonics 365 days requires surgical implant)
+6 more records
Product overview1 text field

Profusa operates as a single platform-plus-modules architecture: one injectable hydrogel biosensor platform (the Profusa Lumee platform) is the unifying technology, and three named products are built on it — Lumee Oxygen (continuous tissue oxygen monitoring for Critical Limb Ischemia and wound care, with EU CE Mark targeted April 2026 and U.S. launch 2027), Lumee Glucose (a 270+ day continuous glucose monitor targeting T1D through prediabetes), and the AI-driven Data Discovery Platform (an NVIDIA-backed cloud platform for clinical intelligence, planned EMR and physician portal integration, and multi-analyte sensing). On top of this core, Profusa has announced a strategic expansion through the planned acquisition of the PanOmics multi-omics diagnostics platform from BioInsights LLC (~$30M in equity securities), extending the company from biosensing into molecular diagnostics, with initial focus on pancreatic cancer applications. The platform is supported by more than $100M of investment (including $30M in DARPA and NIH non-dilutive funding) and 85 global patents granted or pending.

Product and service3 records
1Lumee Oxygen Platform
CategoryContinuous Tissue Oxygen Monitoring
Description

Injectable hydrogel biosensor system providing continuous, real-time tissue oxygen monitoring at the point of care for Critical Limb Ischemia (CLI) patients; includes a subcutaneous hydrogel sensor, a reusable Bluetooth-enabled Lumee Patch optical reader, and the iOS/Android Lumee App, used by vascular surgeons and hospitals.

2Lumee Glucose Platform
CategoryContinuous Glucose Monitoring
Description

Long-duration continuous glucose monitor delivering 270+ days of monitoring from a single standard hypodermic needle injection of a hydrogel microsensor; targeted at T1D through prediabetes patients and projected at ~$900/year, intended for diabetes management and prediabetes coaching.

3Data Discovery Platform
CategoryClinical Data & AI Analytics
Description

AI-driven clinical biochemistry intelligence platform built on NVIDIA infrastructure that converts continuous biochemical sensor data into personalized clinical insights; supports real-time decision support, remote patient monitoring, physician portal integration with EMR and clinical literature, and multi-analyte sensing (oxygen, glucose, lactate, CO2, sodium, ethanol).

Scale indicator20 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-06
Description

Acquisition target of the PanOmics multi-omics diagnostics platform via $30M equity consideration (non-binding Letter of Intent signed March 31, 2026; amended April 3, 2026; asset purchase agreement signed). Includes access to clinical samples, assay design infrastructure, and royalty agreement; targets pancreatic cancer and other multi-indication diagnostic assays. Shareholder approval received June 23, 2026.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-13
Description

Know-how agreement to collaboratively investigate high-impact clinical applications of Profusa's Lumee continuous tissue oxygen monitoring technology, including cardiovascular, renal, multi-organ, and orthopedic indications. Aims to support U.S. commercialization of Lumee for chronic limb threatening ischemia, building on more than a decade of development and $100M+ in investment. Mayo Clinic holds a financial interest in the referenced technology.

3MedSell
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-31
Description

French medical device commercialization specialist distributing Lumee Oxygen tissue monitoring technology in French hospital settings and wound care clinics. Complements the existing collaboration with Groupe Hospitalier Paris Saint Joseph (Dr. Yann Goeffic, ~8% of France's CLI procedures). Targets the ~60,000 CLI procedures/year performed in France.

globenewswire.com
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-15
Description

European distributor for the Lumee Oxygen platform covering Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia — approximately 35% of the EU population. Signed letter of intent in late 2025 to establish European logistics and commercialization infrastructure ahead of Q2 2026 EU launch.

Strategic tierCoreTypeTechnology or Integration
Description

AI technology backbone partner for Profusa's Data Discovery Platform. NVIDIA infrastructure powers the machine learning layer that processes continuous biochemical sensor data, real-time multi-variable analysis, and population-level clinical insights. Selected for best-in-class AI processing capability.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Spanish distributor covering Spanish CLI procedure volume as part of the EU launch. Listed alongside AngioPro GmbH as a confirmed distribution partner in the company's Lumee Oxygen market opportunity disclosures.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Engaged as exclusive financial advisor to Profusa's Board of Directors for the strategic review process initiated in May 2026 to evaluate alternatives including asset transactions, partnerships, and business combinations to maximize shareholder value.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Investor relations and public relations firm managing Profusa's investor inquiries, media inquiries, and SEC filings communications via info@coreir.com.

Strategic tierFlagshipTypeOthers
Description

European Notified Body conducting the EU MDR (Regulation EU 2017 745) conformity assessment for the Lumee Oxygen Platform. Technical file submission completed November 2025; compliance testing in December 2025; review ongoing with response package submitted June 2026; review expected to complete in Q3 or early Q4 2026.

10Austria Medical Center (Dr. Marianne Brodmann)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

European clinical center of excellence performing ~1,500 procedures/year; engaged for the Lumee Oxygen EU launch and the 28-day post-op monitoring clinical workflow.

profusa.com
11Groupe Hospitalier Paris Saint Joseph (Dr. Yann Goeffic)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Paris Vascular Center collaboration; practices account for approximately 8% of all CLTI cases in France. Cited as the foundation of Profusa's existing French clinical footprint ahead of the MedSell distribution partnership.

globenewswire.com
12Belgium Vascular Center (Dr. Koen R. Deloose)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Engaged European clinical center of excellence for the Lumee Oxygen EU launch.

profusa.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight9 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Senseonics manufactures the Eversense implantable CGM, the only commercially approved long-duration implantable continuous glucose monitor. Profusa's Lumee Glucose competes head-to-head with Eversense on the same core proposition (a long-duration injectable/implantable CGM) but with a 270+ day sensor vs Eversense's 180–365 day sensor and a non-surgical hypodermic deployment.

TypeBroad incumbent
Description

Dexcom is the U.S. CGM market leader with multi-billion-dollar revenue and deep payor coverage. Profusa's Lumee Glucose is positioned as a long-duration, lower-cost alternative to Dexcom's 10-day G7 sensor for the broader T2D and prediabetes segments that Dexcom's pricing currently excludes.

3Abbott (Diabetes Care / FreeStyle Libre)
TypeBroad incumbent
Description

Abbott's FreeStyle Libre franchise is the largest installed-base CGM globally. Profusa targets the same diabetes patient population with a fundamentally different value proposition (270+ day single-injection sensor at ~$900/yr vs 14-day wearable Libre sensors), making Abbott a direct competitor in the addressable T2D and prediabetes expansion market.

TypeBroad incumbent
Description

Medtronic offers the Guardian CGM system alongside its insulin pump portfolio and is an integrated diabetes incumbent. While Medtronic's CGM sensor life is short relative to Profusa's, its end-to-end insulin-delivery ecosystem makes it a competitor for any future closed-loop CGM partnership Profusa might pursue.

TypeDirect peer
Description

Masimo is the leader in pulse oximetry and tissue oxygen monitoring technology (SET technology). Profusa's Lumee Oxygen competes in the same clinical oxygen-monitoring category but offers continuous, injectable, long-duration tissue oxygen data vs Masimo's external pulse oximetry and rainbow sensors, positioning Profusa as a direct competitor in the $10.5B oxygen monitoring TAM.

TypeBroad incumbent
Description

Edwards Lifesciences is a global leader in vascular and critical-care monitoring and surgical devices. Profusa's Lumee Oxygen targets the same vascular surgery and CLI customer base that Edwards serves with hemodynamic monitoring, making Edwards a broad incumbent against which Profusa's intra-operative and 28-day post-op monitoring value proposition is evaluated.

TypeEmerging player
Description

iRhythm's Zio long-duration wearable cardiac biosensor shares Profusa's underlying thesis that continuous, multi-day biochemical/physiological monitoring from inside the body creates superior clinical insight versus spot measurements. Both companies pursue KOL-led adoption in specialty clinical workflows.

TypeEmerging player
Description

Biolinq is developing an intradermal microsensor patch for continuous metabolic monitoring. It overlaps with Profusa's multi-analyte biosensor vision and small-form-factor continuous monitoring approach but uses a different (surface-mounted intradermal) delivery modality.

TypeEmerging player
Description

Nemaura is developing a non-invasive CGM (sugarBEAT) and has commercialized a wearable metabolic monitor. It is comparable to Profusa as an emerging player pursuing continuous glucose monitoring outside the incumbent Dexcom/Abbott/Medtronic ecosystem, though with a non-invasive rather than injectable architecture.

TypeEmerging player
Description

GlucoTrack is developing a non-invasive continuous glucose monitor. It competes for the same T2D and prediabetes patient segments that Profusa targets with Lumee Glucose, representing an alternative technology path (non-invasive) to Profusa's long-duration injectable sensor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Profusa

Implantable Medical Biosensorsprofusa.com

Profusa is a medical device company commercializing injectable hydrogel biosensors for continuous tissue oxygen monitoring in critical limb ischemia and a long-duration continuous glucose monitor, with a planned multi-omics diagnostics expansion.

What Profusa does

Profusa is a medical device company developing injectable, biologically compatible hydrogel microsensors (sub-millimeter diameter) that integrate with surrounding tissue to enable continuous, real-time biochemical monitoring from inside the body for 9+ months from a single hypodermic needle injection. The core hydrogel architecture is paired with a reusable Bluetooth-enabled optoelectronic reader patch, a smartphone application (iOS/Android), a cloud backend, and an NVIDIA-backed machine-learning layer that compensates for individual tissue variation to maintain accuracy over months without recalibration. The platform is supported by 85 global patents and more than $100M of cumulative investment, including $30M+ in non-dilutive grants from DARPA and NIH.

Profusa commercializes this platform through three product lines. Lumee Oxygen is an injectable tissue oxygen sensor delivering intra-operative and 28-day post-operative real-time oxygen monitoring for Critical Limb Ischemia intervention — a use case validated by a 2015 Journal of Vascular Surgery publication — with EU CE Mark conformity assessment under GMED targeted for Q3–early Q4 2026 and an FDA pivotal study targeted Q1 2026. Lumee Glucose is a continuous glucose monitor delivering 270+ days of monitoring from a single injection, with clinical-trial MARD of 10–12% and a projected ~$900/yr cost at >80% gross margin, targeting the full diabetes spectrum from T1D through prediabetes. The Data Discovery Platform converts continuous biochemical streams into clinical insights, with planned EMR integration and a physician portal. Profusa has also announced a ~$30M LOI to acquire BioInsights' PanOmics multi-omics diagnostics platform to extend into molecular diagnostics, initially targeting pancreatic cancer.

Commercially, Profusa is essentially pre-revenue with a planned FY2026 launch in Europe and the U.S. The company generates revenue today via per-procedure sales of CLI sensors at €600–€800 per case, €10,000 starter kits (3 kits/center/year), a service-based CRO research-use-only offering, and (planned) ~$900/yr subscription pricing for the future Lumee Glucose CGM. Distribution in Europe is anchored by AngioPro GmbH (Germany, Benelux, Austria, UK, Scandinavia), MedSell (France), and Dismeval (Spain), collectively covering roughly 35% of the EU population and ~200,000 annual Critical Limb Threatening Ischemia cases. Anchor clinical centers of excellence — Austria Medical Center, Paris Vascular Center, and Belgium Vascular Center — are pre-engaged. The company became public on Nasdaq via a July 2025 business combination with NorthView Acquisition Corp (ticker PFSA) and has since assembled a $22M PIPE, a $100M Equity Line of Credit with Ascent Partners, and additional convertible note facilities; it is also pursuing a strategic review with Tungsten Advisors amid a going-concern flag, Nasdaq listing transfer to the Capital Market tier, and shareholder-approved reverse stock split and debt conversion.

Profusa firmographics

Firmographics
Name
Profusa
Legal name
Profusa, Inc.
Website
https://profusa.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
51–100 employees
Short description
Profusa is a medical device company commercializing injectable hydrogel biosensors for continuous tissue oxygen monitoring in critical limb ischemia and a long-duration continuous glucose monitor, with a planned multi-omics diagnostics expansion.
Ownership category
akta.pro rank

Profusa industry classification

Industry
Product category
Implantable Medical Biosensors
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)

Keywords

  • Implantable biosensors
  • Continuous tissue monitoring
  • Tissue oxygen monitoring
  • Continuous glucose monitoring
  • Medical device manufacturing

Where Profusa is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Profusa business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D

Revenue model

  1. Procedure Revenue (CLI Sensors): Per-procedure sale of 4 sensors + 4 injection pens per CLI case, priced at €600–€800 per procedure, recurring with case volume at vascular surgery centers.
  2. Starter Kit Sales: One-time sale of starter kits (iPad + preloaded software + sensors + adhesives) priced at €10,000 per kit, with target of 3 kits per center per year covering 200–1,500 procedures depending on center volume.
  3. Contract Research Organization (CRO) Research Services: Service-based revenue from Lumee tissue oxygen platform deployed as research-use-only (RUO) offering in the CRO market for pharmaceutical R&D, preclinical studies, toxicology, wound healing, and oncology research applications; commercially available and targeted at $47.9B (2025) global CRO market.
  4. Future Data Monetization & AI-Driven Insights: Planned/optional stream where Profusa's growing clinical dataset of real-time biochemical measurements is monetized through partnerships, research collaborations, and the physician portal; positioned as a compounding data asset.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCLI Procedure: €600–€800 per procedure (4 sensors + 4 pens)
One time/ perpetual licensePay-as-you-goStarter Kit: €10,000 per kit
SubscriptionAnnualLumee Glucose CGM: ~$900/year projected
OtherPay-as-you-goCRO Research-Use-Only Service (custom)

Go-to-market motion5 records

Distribution channels1 record

Marketing channels8 records

Profusa product offering

Product offering

Core offering

Profusa develops and manufactures an injectable, biologically compatible hydrogel microsensor platform that integrates with surrounding tissue to provide continuous, real-time biochemical monitoring for 9+ months from a single injection. Its commercial products include the Lumee Oxygen Platform (intra-operative and 28-day post-operative tissue oxygen monitoring for Critical Limb Ischemia), the Lumee Glucose Platform (a 270+ day continuous glucose monitor), and the AI-driven Data Discovery Platform (an NVIDIA-backed cloud analytics layer with planned EMR and physician portal integration).

Product overview

Profusa operates as a single platform-plus-modules architecture: one injectable hydrogel biosensor platform (the Profusa Lumee platform) is the unifying technology, and three named products are built on it — Lumee Oxygen (continuous tissue oxygen monitoring for Critical Limb Ischemia and wound care, with EU CE Mark targeted April 2026 and U.S. launch 2027), Lumee Glucose (a 270+ day continuous glucose monitor targeting T1D through prediabetes), and the AI-driven Data Discovery Platform (an NVIDIA-backed cloud platform for clinical intelligence, planned EMR and physician portal integration, and multi-analyte sensing). On top of this core, Profusa has announced a strategic expansion through the planned acquisition of the PanOmics multi-omics diagnostics platform from BioInsights LLC (~$30M in equity securities), extending the company from biosensing into molecular diagnostics, with initial focus on pancreatic cancer applications. The platform is supported by more than $100M of investment (including $30M in DARPA and NIH non-dilutive funding) and 85 global patents granted or pending.

Differentiator

Problem solved

Functional benefit

Brands

  • Lumee: Product line of injectable hydrogel biosensor platforms for continuous tissue oxygen (Lumee Oxygen) and glucose (Lumee Glucose) monitoring, with companion Lumee Patch optical reader and Lumee App for iOS/Android.
  • Data Discovery Platform

Products and services

  • Lumee Oxygen Platform Injectable hydrogel biosensor system providing continuous, real-time tissue oxygen monitoring at the point of care for Critical Limb Ischemia (CLI) patients; includes a subcutaneous hydrogel sensor, a reusable Bluetooth-enabled Lumee Patch optical reader, and the iOS/Android Lumee App, used by vascular surgeons and hospitals.
  • Lumee Glucose Platform Long-duration continuous glucose monitor delivering 270+ days of monitoring from a single standard hypodermic needle injection of a hydrogel microsensor; targeted at T1D through prediabetes patients and projected at ~$900/year, intended for diabetes management and prediabetes coaching.
  • Data Discovery Platform AI-driven clinical biochemistry intelligence platform built on NVIDIA infrastructure that converts continuous biochemical sensor data into personalized clinical insights; supports real-time decision support, remote patient monitoring, physician portal integration with EMR and clinical literature, and multi-analyte sensing (oxygen, glucose, lactate, CO2, sodium, ethanol).

Quantifiable outcome

  • 270+ day sensor functional life vs 7–14 days for conventional CGM devices (Senseonics 365 days requires surgical implant)
  • +6 more outcomes

Companies that use Profusa

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Profusa technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature8 records

Profusa partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered flagship, core and minor.

  • BioInsights LLC (PanOmics platform)flagshipStrategic or Co-development Partner · 6 April 2026Acquisition target of the PanOmics multi-omics diagnostics platform via $30M equity consideration (non-binding Letter of Intent signed March 31, 2026; amended April 3, 2026; asset purchase agreement signed). Includes access to clinical samples, assay design infrastructure, and royalty agreement; targets pancreatic cancer and other multi-indication diagnostic assays. Shareholder approval received June 23, 2026.
  • Mayo ClinicflagshipStrategic or Co-development Partner · 13 February 2026Know-how agreement to collaboratively investigate high-impact clinical applications of Profusa's Lumee continuous tissue oxygen monitoring technology, including cardiovascular, renal, multi-organ, and orthopedic indications. Aims to support U.S. commercialization of Lumee for chronic limb threatening ischemia, building on more than a decade of development and $100M+ in investment. Mayo Clinic holds a financial interest in the referenced technology.
  • MedSellcoreChannel Partner/ Reseller/ Distributor · 31 December 2025French medical device commercialization specialist distributing Lumee Oxygen tissue monitoring technology in French hospital settings and wound care clinics. Complements the existing collaboration with Groupe Hospitalier Paris Saint Joseph (Dr. Yann Goeffic, ~8% of France's CLI procedures). Targets the ~60,000 CLI procedures/year performed in France.
  • AngioPro GmbHflagshipChannel Partner/ Reseller/ Distributor · 15 October 2025European distributor for the Lumee Oxygen platform covering Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia — approximately 35% of the EU population. Signed letter of intent in late 2025 to establish European logistics and commercialization infrastructure ahead of Q2 2026 EU launch.
  • NVIDIAcoreTechnology or IntegrationAI technology backbone partner for Profusa's Data Discovery Platform. NVIDIA infrastructure powers the machine learning layer that processes continuous biochemical sensor data, real-time multi-variable analysis, and population-level clinical insights. Selected for best-in-class AI processing capability.
  • Dismeval, S.L.coreChannel Partner/ Reseller/ DistributorSpanish distributor covering Spanish CLI procedure volume as part of the EU launch. Listed alongside AngioPro GmbH as a confirmed distribution partner in the company's Lumee Oxygen market opportunity disclosures.
  • Tungsten AdvisorscoreImplementation/ SI/ Consulting PartnerEngaged as exclusive financial advisor to Profusa's Board of Directors for the strategic review process initiated in May 2026 to evaluate alternatives including asset transactions, partnerships, and business combinations to maximize shareholder value.
  • CORE IRcoreImplementation/ SI/ Consulting PartnerInvestor relations and public relations firm managing Profusa's investor inquiries, media inquiries, and SEC filings communications via info@coreir.com.
  • GMED SAS (Notified Body NB 0459)flagshipOthersEuropean Notified Body conducting the EU MDR (Regulation EU 2017 745) conformity assessment for the Lumee Oxygen Platform. Technical file submission completed November 2025; compliance testing in December 2025; review ongoing with response package submitted June 2026; review expected to complete in Q3 or early Q4 2026.
  • Austria Medical Center (Dr. Marianne Brodmann)coreStrategic or Co-development PartnerEuropean clinical center of excellence performing ~1,500 procedures/year; engaged for the Lumee Oxygen EU launch and the 28-day post-op monitoring clinical workflow.
  • Groupe Hospitalier Paris Saint Joseph (Dr. Yann Goeffic)coreStrategic or Co-development PartnerParis Vascular Center collaboration; practices account for approximately 8% of all CLTI cases in France. Cited as the foundation of Profusa's existing French clinical footprint ahead of the MedSell distribution partnership.
  • Belgium Vascular Center (Dr. Koen R. Deloose)minorStrategic or Co-development PartnerEngaged European clinical center of excellence for the Lumee Oxygen EU launch.

Scale indicators20 records

Recent moves8 records

Expansion highlights9 records

Profusa competitors and assessment

Company assessment

Direct peers

  • Senseonics Holdings: Senseonics manufactures the Eversense implantable CGM, the only commercially approved long-duration implantable continuous glucose monitor. Profusa's Lumee Glucose competes head-to-head with Eversense on the same core proposition (a long-duration injectable/implantable CGM) but with a 270+ day sensor vs Eversense's 180–365 day sensor and a non-surgical hypodermic deployment.
  • Masimo: Masimo is the leader in pulse oximetry and tissue oxygen monitoring technology (SET technology). Profusa's Lumee Oxygen competes in the same clinical oxygen-monitoring category but offers continuous, injectable, long-duration tissue oxygen data vs Masimo's external pulse oximetry and rainbow sensors, positioning Profusa as a direct competitor in the $10.5B oxygen monitoring TAM.

Broad incumbents

  • Dexcom: Dexcom is the U.S. CGM market leader with multi-billion-dollar revenue and deep payor coverage. Profusa's Lumee Glucose is positioned as a long-duration, lower-cost alternative to Dexcom's 10-day G7 sensor for the broader T2D and prediabetes segments that Dexcom's pricing currently excludes.
  • Abbott (Diabetes Care / FreeStyle Libre): Abbott's FreeStyle Libre franchise is the largest installed-base CGM globally. Profusa targets the same diabetes patient population with a fundamentally different value proposition (270+ day single-injection sensor at ~$900/yr vs 14-day wearable Libre sensors), making Abbott a direct competitor in the addressable T2D and prediabetes expansion market.
  • Medtronic (Diabetes): Medtronic offers the Guardian CGM system alongside its insulin pump portfolio and is an integrated diabetes incumbent. While Medtronic's CGM sensor life is short relative to Profusa's, its end-to-end insulin-delivery ecosystem makes it a competitor for any future closed-loop CGM partnership Profusa might pursue.
  • Edwards Lifesciences: Edwards Lifesciences is a global leader in vascular and critical-care monitoring and surgical devices. Profusa's Lumee Oxygen targets the same vascular surgery and CLI customer base that Edwards serves with hemodynamic monitoring, making Edwards a broad incumbent against which Profusa's intra-operative and 28-day post-op monitoring value proposition is evaluated.

Emerging players

  • iRhythm Technologies: iRhythm's Zio long-duration wearable cardiac biosensor shares Profusa's underlying thesis that continuous, multi-day biochemical/physiological monitoring from inside the body creates superior clinical insight versus spot measurements. Both companies pursue KOL-led adoption in specialty clinical workflows.
  • Biolinq: Biolinq is developing an intradermal microsensor patch for continuous metabolic monitoring. It overlaps with Profusa's multi-analyte biosensor vision and small-form-factor continuous monitoring approach but uses a different (surface-mounted intradermal) delivery modality.
  • Nemaura Medical: Nemaura is developing a non-invasive CGM (sugarBEAT) and has commercialized a wearable metabolic monitor. It is comparable to Profusa as an emerging player pursuing continuous glucose monitoring outside the incumbent Dexcom/Abbott/Medtronic ecosystem, though with a non-invasive rather than injectable architecture.
  • GlucoTrack: GlucoTrack is developing a non-invasive continuous glucose monitor. It competes for the same T2D and prediabetes patient segments that Profusa targets with Lumee Glucose, representing an alternative technology path (non-invasive) to Profusa's long-duration injectable sensor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Profusa social profiles

Digital presence

Profusa compliance and trust

Trust signal

Compliance2 records

Profusa financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Profusa leadership team

Management profile

Number of profiles

Profiles6 records

Profusa subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Profusa funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Profusa M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Profusa

What does Profusa do?

Profusa develops and manufactures an injectable, biologically compatible hydrogel microsensor platform that integrates with surrounding tissue to provide continuous, real-time biochemical monitoring for 9+ months from a single injection. Its commercial products include the Lumee Oxygen Platform (intra-operative and 28-day post-operative tissue oxygen monitoring for Critical Limb Ischemia), the Lumee Glucose Platform (a 270+ day continuous glucose monitor), and the AI-driven Data Discovery Platform (an NVIDIA-backed cloud analytics layer with planned EMR and physician portal integration).

Is Profusa a public or private company?

Profusa is a public company. It is classified as public and is currently operating.

When was Profusa founded?

Profusa was founded in 2009. It employs 51 to 100 people.

Where is Profusa based?

Profusa is headquartered in Emeryville, United States, in the North America region.

How does Profusa make money?

Four revenue lines are on record. Procedure Revenue (CLI Sensors) is the primary driver. The others are starter Kit Sales, contract Research Organization (CRO) Research Services and future Data Monetization & AI-Driven Insights.

Who are Profusa's main competitors?

Direct peers on record are Senseonics Holdings and Masimo. Broad incumbents are Dexcom, Abbott (Diabetes Care / FreeStyle Libre), Medtronic (Diabetes) and Edwards Lifesciences. Emerging players are iRhythm Technologies, Biolinq, Nemaura Medical and GlucoTrack.

Does Profusa have an API?

No public API is recorded for Profusa.

What industry is Profusa in?

Profusa's product category is Implantable Medical Biosensors. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialProfusa Announces Progress Towards Satisfying The Conditions To Close Of The Option Agreement With G3Profusa reported FY2025 revenue of $108.02 million, net loss of $2.38 million, and adjusted EBITDA of $4.96 million. The company is making progress toward satisfying conditions to close the option agreement with G3, which would combine into a public diagnostics company.TradingViewProfusa Lowers Note Conversion Price Floor to $0.20 in Amendment With NorthView SponsorProfusa amended its Note Modification and Conversion Agreement with NorthView Sponsor, setting the conversion price floor at $0.20 per share or the prior trading day's closing price, whichever is greater. The amendment, effective Nov 5, 2026, applies to conversion notices delivered on or after that date.Defense WorldProfusa, Inc. (NASDAQ:PFSA) Stock Short Interest Report for OctoberProfusa's short interest fell 51.5% to 77,845 shares as of October 15th, with 15.1% of shares short sold. Major shareholder Financial Lp Hrt sold 10,602 shares at $3.56, reducing its stake by 36.37%. Analysts rate the stock a sell.Ticker ReportProfusa, Inc. (NASDAQ:PFSA) Sees Large Growth in Short InterestProfusa's short interest rose 409.3% to 160,653 shares as of September 30th, with 31.2% of shares short sold. The stock traded down 8.5% to $1.30, and the consensus analyst rating is Sell. The company reported a quarterly loss of $151.80 EPS.Markets DailyProfusa, Inc. (NASDAQ:PFSA) Stock Short Interest Rises 409.3%Short interest in Profusa, Inc. rose 409.3% to 160,653 shares as of September 30th, with 31.2% of shares sold short. Analysts have a consensus "Sell" rating, and the company reported a quarterly loss of $151.80 per share.Markets DailyHead-To-Head Contrast: Profusa (NASDAQ:PFSA) and OraSure Technologies (NASDAQ:OSUR)OraSure Technologies beats Profusa on 7 of 13 factors, including profitability and analyst ratings. OraSure has higher revenue, lower P/E, and a consensus price target of $3.00, while Profusa is a shell company seeking a merger.Defense WorldHead to Head Review: OraSure Technologies (NASDAQ:OSUR) and Profusa (NASDAQ:PFSA)OraSure Technologies beats Profusa on 7 of 13 factors, including profitability, institutional ownership, and valuation. OraSure has a consensus price target of $3.00, implying a 23.66% downside, while Profusa has no price target. The comparison highlights OraSure's stronger analyst ratings and institutional backing.Quiver QuantitativeProfusa jumps as CE-mark progress update appears to spark speculative buying | PFSA Stock NewsProfusa shares rose 42.9% after a September 24 update on CE-mark progress for its Lumee Oxygen Platform, including a positive ISO 13485 certification decision and an expected early October certification. The move was amplified by the stock's small share count and heavy trading volume, while insiders have made 6 purchases and 5 sales in the past six months.TipranksWhy Is Penny Stock Profusa (PFSA) Up Today?Profusa's stock surged 71.22% premarket after GMED approved its ISO 13485 quality management system, a step toward the Lumee Oxygen Platform's EU CE mark. The company said no date was set for the review's end or the mark. Analysts rate the stock Neutral with a $2 target.Medical BuyerProfusa gets Nasdaq compliance determinationProfusa, Inc. received a Nasdaq letter confirming compliance with Listing Rules 5550(a)(2) and 5550(b)(1). The company faces a one-year Mandatory Panel Monitor; failure to meet equity rules triggers a delist determination, appealable by hearing request.